Amicus Therapeutics names Dr. Andrew Mulberg VP: 5 points

Amicus Therapeutics appointed Andrew E. Mulberg, MD, vice president, regulatory strategy.

Here are five points:

1. Dr. Mulberg, a pediatric gastroenterologist, will oversee global regulatory strategies for all Amicus programs.

2. Most recently, Dr. Mulberg served as deputy director of the FDA's Division of Gastroenterology and Inborn Errors Products.

3. He also previously worked in global drug development and medical affairs at pharmaceutical companies, including Johnson & Johnson.

4. He is also a member of the American Gastroenterological Association and North American Society for Pediatric Gastroenterology and Nutrition.

5. Amicus Therapeutics is a global biotechnology company focusing on therapies for rare and orphan diseases.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast